ReviewFEMS microbiology reviews2019
Impact of nanosystems in Staphylococcus aureus biofilms treatment.
Review in FEMS microbiology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Fatty Acids as Prebiotics and Their Role in Antibiofilm Activity.Antibiotics (Basel, Switzerland) · 2026Review
- Enhancing the Antimicrobial Effectiveness of Zinc Oxide Nanoparticles Against Staphylococcus aureus, Through Combination with Potassium and Zingerone.Current microbiology · 2025Article
- A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistantPharmaceutical nanotechnology · 2025Review
- Biocompatibility and antibacterial properties of medical stainless steel and titanium modified by alumina and hafnia films prepared by atomic layer deposition.Journal of materials science. Materials in medicine · 2024Article
- Lentisk (Pharmaceutics · 2024Article
- Biofilm-producing ability of methicillin-resistant Staphylococcus aureus clinically isolated in China.BMC microbiology · 2024Article
- Liposomal Rifabutin-A Promising Antibiotic Repurposing Strategy against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- Phage Lytic Protein CHAPSH3b Encapsulated in Niosomes and Gelatine Films.Microorganisms · 2024Article
- Approaches to combating methicillin-resistantExpert opinion on investigational drugs · 2024Article
- Non disseminative nano-strategy against in vivo Staphylococcus aureus biofilms.NPJ biofilms and microbiomes · 2023Article
- Nanotechnology Involved in Treating Urinary Tract Infections: An Overview.Nanomaterials (Basel, Switzerland) · 2023Review
- Regulation ofPharmaceutics · 2023Review
- Rhamnolipid Micelles Assist Azithromycin in Efficiently DisruptingInternational journal of nanomedicine · 2023Article
- Surface modification of titanium substrate via combining photothermal therapy and quorum-sensing-inhibition strategy for improving osseointegration and treating biofilm-associated bacterial infection.Bioactive materials · 2022Article
- Insights into the antimicrobial effects of ceritinib against Staphylococcus aureus in vitro and in vivo by cell membrane disruption.AMB Express · 2022Article
- Review
- Current treatments for biofilm-associated periprosthetic joint infection and new potential strategies.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022Review
- Effect of Biosynthesized Silver Nanoparticles on Bacterial Biofilm Changes inNanomaterials (Basel, Switzerland) · 2022Article
- The prevalence of virulence determinants in methicillin-resistant Staphylococcus aureus isolated from different infections in hospitalized patients in Poland.Scientific reports · 2022Article
- Ciprofloxacin-Loaded Gold Nanoparticles against Antimicrobial Resistance: An In Vivo Assessment.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus (S. aureus) is considered by the World Health Organization as a high priority pathogen for which new therapies are needed. This is particularly important for biofilm implant-associated infections once the only available treatment option implies a surgical procedure combined with antibiotic therapy. Consequently, these infections represent an economic burden for Healthcare Systems. A new strategy has emerged to tackle this problem: for small bugs, small particles. Here, we describe how nanotechnology-based systems have been studied to treat S. aureus biofilms. Their features, drawbacks and potentialities to impact the treatment of these infections are highlighted. Furthermore, we also outline biofilm models and assays required for preclinical validation of those nanosystems to smooth the process of clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.